Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Calithera Biosciences Inc CALA

Healthcare Biotechnology
Calithera Biosciences, Inc. is a shell company. The Company is winding up its operations. The Company is seeking to sell all of its clinical assets and programs. The Company has not generated any revenue.

Recent & Breaking News (GREY:CALA)

Calithera Biosciences Announces Update on Complete Liquidation and Dissolution

GlobeNewswire June 29, 2023

Calithera Biosciences Announces Update on Complete Liquidation and Dissolution

GlobeNewswire May 19, 2023

Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution

GlobeNewswire January 9, 2023

Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update

GlobeNewswire November 14, 2022

Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

GlobeNewswire November 8, 2022

Calithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung Cancer

GlobeNewswire October 3, 2022

Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 6, 2022

Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

GlobeNewswire August 15, 2022

Calithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022

GlobeNewswire August 8, 2022

Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences

GlobeNewswire July 13, 2022

Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Sapanisertib in Relapsed/Refractory NRF2 (NFE2L2)-Mutated Squamous Non-Small Cell Lung Cancer

GlobeNewswire July 6, 2022

Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB (ABC) Diffuse Large B-Cell Lymphoma

GlobeNewswire June 23, 2022

Calithera Biosciences Announces 1-for-20 Reverse Stock Split

GlobeNewswire June 14, 2022

Calithera to Present at the H.C. Wainwright Global Investment Conference

GlobeNewswire May 17, 2022

Calithera Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights

GlobeNewswire May 10, 2022

Calithera Biosciences to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022

GlobeNewswire May 3, 2022

Calithera Presents Data Highlighting Discovery of Novel Series of Promising Synthetic Lethal Compounds

GlobeNewswire April 8, 2022

Calithera Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

GlobeNewswire March 31, 2022

Calithera Biosciences, Inc. Prices $10.0 Million Underwritten Public Offering of Common Stock and Warrants to Purchase Common Stock

GlobeNewswire March 30, 2022

Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock and Warrants to Purchase Common Stock

GlobeNewswire March 29, 2022